| 摘要 |
FIELD: chemistry. ^ SUBSTANCE: invention relates to a new crystalline polymorph of 3-(N-methyl-N-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid monosodium salt monohydrate (Ibandronate) with formula I, which is characterised by x-ray powder diffraction pattern with characteristic peaks at angles 2-theta: 9.7, 12.2, 14.4, 16.8 and 25.8, IR-spectrum with characteristic peaks, cm-1: 3679, 3164, 2955; 2854, 1377, 1290, 1157, 1093, 1068, 1035, 965, 951, 933, 905, 761 and 723, as well as a vibrational Raman spectrum with characteristic peaks, cm-1: 2968, 2951, 2928, 2887, 2849, 1441, 1308, 1136, 1056, 1023, 954, 907, 839, 762 and 678. formula I. ^ EFFECT: obtaining a new crystalline ibandronate polymorph used for controlling hypercalcemia, having improved solubility. ^ 13 cl, 6 dwg, 6 ex, 1 tbl |
